Answers are grounded in this paper and cite their sources.
Hematocrit predicts variability in tacrolimus whole blood concentrations but is not expected to influence unbound (therapeutically active) concentrations. Fat-free mass, CYP3A5 genotype, sex, age and time after transplant influence the tacrolimus individual dose requirement. Because hematocrit is highly variable in kidney transplant patients and increases substantially after kidney transplantation, hematocrit is a key factor in the interpretation of tacrolimus whole blood concentrations.
No takes yet. Share an insight, caveat, or question.
Størset et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: